argenx logo
ARGXargenx
Trade ARGX now
argenx primary media

About argenx

argenx (NASDAQ:ARGX), (EURONEXT:ARGX) is a biotechnology company focused on developing antibody-based therapies for the treatment of severe autoimmune diseases and cancer. With a deep and diverse pipeline, argenx aims to disrupt conventional treatment approaches by discovering novel antibodies that have the potential to transform patient outcomes. The company's flagship project, efgartigimod, targets a range of autoimmune conditions, showcasing argenx's commitment to addressing unmet medical needs. Through strategic collaborations and rigorous scientific research, argenx continues to push the boundaries of medicine to improve the lives of patients around the world.

What is ARGX known for?

Snapshot

Public US
Ownership
2008
Year founded
1259
Employees
Breda, Netherlands
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Kingdom of the Netherlands

Products and/or services of argenx

  • Efgartigimod (Vyvgart) - a first-in-class neonatal Fc receptor blocker for treating generalized myasthenia gravis and primary immune thrombocytopenia.
  • Cusatuzumab - an anti-CD70 antibody for the potential treatment of hematological malignancies, including acute myeloid leukemia (AML).
  • ARGX-117 - a C2 inhibitor aimed at addressing complement-mediated diseases for which current treatments are insufficient.
  • ARGX-114 - an anti-Met antibody designed for the treatment of solid tumors, exploring its use in various types of cancer.
  • ARGX-119 - an early-stage therapeutic aimed at Amyotrophic Lateral Sclerosis (ALS) and other neuromuscular disorders.
  • Collaboration with Halozyme Therapeutics to use ENHANZE drug delivery technology, enhancing the administration of its therapeutic antibodies.

argenx executive team

  • Mr. Timothy Van Hauwermeiren EMBA, M.Sc.Co-Founder, CEO & Executive Director
  • Mr. Karl GubitzChief Financial Officer
  • Ms. Karen MasseyChief Operating Officer
  • Dr. Peter UlrichtsChief Scientific Officer
  • Ms. Malini MoorthyGeneral Counsel
  • Mr. Arjen Lemmen M.Sc.Vice President of Corporate Development & Strategy
  • Ms. Andria WilkGlobal Head of Quality
  • Dr. Luc TruyenChief Medical Officer
  • Prof. Hans de Haard Ir, Ph.D.Co-Founder & Member of Board Advisors
  • Mr. Filip BorgionsChief Technology Innovation Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.